The Canadian Agency for Drugs and Technologies in Health, the Canadian entity responsible for health technology assessments, has announced that it has revised its approach to reviewing biosimilars.
The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health technology assessments, has announced that it has revised its approach to reviewing biosimilars. CADTH says that its new process will provide for shorter timelines, fewer submission requirements, and an abbreviated biosimilar summary dossier template for manufacturers’ use.
CADTH reports that its experience in reviewing biosimilars, together with stakeholder input gathered through an open consultation in 2017—which garnered input from 25 individuals and organizations—allowed the organization to identify key areas for improvement in its internal processes.
The new procedure will reduce the number of submission requirements that manufacturers must meet when submitting a biosimilar summary dossier (a document in which manufacturers provide all relevant information for a biosimilar product for the pan-Canadian Pharmaceutical Alliance and participating Canadian jurisdictions to make decision about which products to include in their drug plans). The dossier is intended to give CADTH the information it needs to assess the cost of biosimilars, consolidate stakeholder feedback, and identify potential implementation issues.
In the biosimilar dossier, manufacturers must submit drug pricing information for the smallest dispensable unit of the biosimilar—for all packaging formats—and must not be exceeded for any of the drug plans that choose to adopt the biosimilar after the review process has been completed. The price for the drug must be reported for 4 decimal places, and will be disclosed in all CADTH reports. The price submitted is used in the pharmacoeconomic evaluation of the biosimilar, and in budget impact analyses for the models used in individual Canadian provinces’ health plans.
The department may also choose to review evidence from switching studies from the reference biologic to the biosimilar on a case-by-case basis, and says that “This determination is made in consultation with the participating public drug plans and may be influenced by the volume and quality of available evidence, as well as reimbursement and switching policies for other biosimilars for the same reference drug and/or indications.” CADTH will also collect and summarize input from patient groups, and will share that input with drug plans.
After reviewing all of the submitted information, CADTH’s reviewers will provide summary of stakeholder input comment on the manufacturer’s cost information, and forward its summary dossier to both the applicant and participating drug plans for a determination. CADTH’s biosimilar summary dossiers will also be available publicly and without redaction.
CADTH’s new submission process took effect on February 13, and is expected to reduce the overall biosimilar review timeline from 6 months to 3 months.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.